Daily Endocrinology Research Analysis
Analyzed 46 papers and selected 3 impactful papers.
Summary
Today's top endocrinology papers span mechanistic immunology, perioperative endocrine outcomes, and drug safety. A Science Advances study implicates galectin-3 in type 1 diabetes via suppression of regulatory T cells, suggesting a tractable target. Large-scale clinical evidence links GLP-1/GIP receptor agonist use to lower short-term hypocalcemia after thyroidectomy, and a rigorous meta-analysis contextualizes the low absolute risk of NAION with semaglutide.
Research Themes
- Immunoendocrine mechanisms in type 1 diabetes
- Perioperative endocrine surgery outcomes and incretin therapies
- Pharmacovigilance of GLP-1-based therapies and ocular safety
Selected Articles
1. Galectin-3 exacerbates autoimmune diabetes by limiting regulatory T cell differentiation and function.
T1D patients and their first-degree relatives exhibit elevated serum galectin-3, largely from monocytes/macrophages. Both pharmacologic inhibition (TD139) and genetic deletion mitigated galectin-3–mediated suppression of regulatory T cells, identifying a mechanistic axis that may be therapeutically tractable.
Impact: This work links a measurable circulating lectin to impaired Treg biology in T1D and shows reversibility with an existing inhibitor, pointing to rapid translational potential.
Clinical Implications: Galectin-3 may serve as a biomarker for at-risk individuals (including first-degree relatives) and a therapeutic target; clinical trials of galectin-3 inhibition (e.g., TD139) in T1D prevention or modulation warrant consideration.
Key Findings
- Serum galectin-3 levels were significantly elevated in T1D patients and their first-degree relatives compared with healthy controls.
- Monocytes/macrophages were identified as the main source of circulating galectin-3.
- Pharmacologic inhibition with TD139 and galectin-3 gene knockout attenuated galectin-3–mediated suppression of regulatory T cells.
Methodological Strengths
- Integration of human clinical observations with interventional mechanistic approaches (pharmacologic inhibition and gene knockout).
- Identification of cellular source (monocytes/macrophages) strengthens biological plausibility.
Limitations
- Sample size and detailed cohort characteristics are not provided in the abstract.
- Cross-sectional human comparisons limit causal inference; translational efficacy in patients remains to be tested.
Future Directions: Prospective studies testing galectin-3 inhibition in at-risk relatives or recent-onset T1D, alongside validation of galectin-3 as a predictive biomarker.
Galectin-3, a β-galactoside-binding lectin, has been implicated in several inflammatory and autoimmune diseases. However, the significance of circulating Galectin-3 in type 1 diabetes (T1D) remains unclear. Here, we report that compared to healthy controls, patients with T1D and their first-degree relatives (FDRs) exhibited significantly increased serum Galectin-3 levels primarily produced and secreted by monocytes/macrophages. Pharmacological inhibition (TD139) as well as knockout of Galectin-3 gene both attenuated Galectin-3-mediated suppression of regulatory T cells (T
2. Rate and risk of non-arteritic anterior ischaemic optic neuropathy with semaglutide use for diabetes and weight loss: a systematic review and meta-analysis.
Across 8 RCTs and 8 observational studies, NAION incidence in semaglutide users was low. An increased hazard for NAION appeared in observational diabetes cohorts (HR 1.85), but RCTs did not corroborate this signal; weight-loss cohorts showed no significant increase. Findings support continued pharmacovigilance while contextualizing low absolute risk.
Impact: This is the most comprehensive synthesis to date, separating indication and study design to clarify conflicting safety signals about a widely used endocrine therapy.
Clinical Implications: Clinicians can counsel patients that absolute NAION risk on semaglutide is low. Heightened vigilance may be prudent in diabetes populations, but current RCT evidence does not mandate therapy changes; prompt evaluation of new visual symptoms remains essential.
Key Findings
- Included 8 RCTs (31,174 patients) and 8 observational studies (1,611,278 patients) with stratified analyses by indication and design.
- Observational diabetes cohorts showed increased NAION hazard (HR 1.85, 95% CI 1.20–2.85), while RCTs showed no significant risk increase (RR 1.76, 95% CI 0.43–7.25).
- Absolute NAION incidence remained low across groups; weight-loss cohorts did not show a significant risk increase.
Methodological Strengths
- Comprehensive multi-database search including registries and sponsor contact, incorporating unpublished data.
- Stratification by clinical indication and study design with sensitivity analyses addressing patient overlap.
Limitations
- NAION is rare, yielding few events and wide confidence intervals, especially in RCTs.
- Residual confounding in observational studies and potential heterogeneity across datasets.
Future Directions: Prospective pharmacovigilance registries with standardized ophthalmic endpoints and linkage to prescribing data; pooled individual patient data meta-analyses to refine subgroup risks.
TOPIC: This systematic review and meta-analysis evaluates the rate and risk of non-arteritic anterior ischemic optic neuropathy (NAION) in adults receiving semaglutide for diabetes or weight loss. CLINICAL RELEVANCE: Semaglutide is a transformative treatment for diabetes and obesity. NAION is a serious cause of sudden, often permanent, vision loss. A comprehensive synthesis of available and conflicting evidence of a potential link is needed to inform clinical practice. METHODS: Our comprehensive search included MEDLINE, Embase, CENTRAL, clinical trial registries, and direct contact with trial sponsors to identify unpublished data from inception to March 2025. We included randomised-controlled trials (RCTs) and observational studies evaluating semaglutide versus placebo or standard therapy in adults. Incident NAION was the primary outcome. Pooled incidence rates, hazard ratios (HRs) and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models, uniquely stratified by both clinical indication (diabetes/weight loss) and study design. RESULTS: Our search identified eight RCTs (31,174 patients, including three RCTs not previously synthesised in meta-analyses) and eight observational studies (1,611,278 patients) were included. Observational studies for diabetes showed a pooled NAION incidence of 26.7 per 100,000 person-years in those on semaglutide versus 18.9 per 100,000 person-years in those not on semaglutide (HR1.85, 95% CI 1.20-2.85). RCTs for diabetes demonstrated five ischaemic optic neuropathy events in those on semaglutide versus one in those not, with no significant evidence of increased risk (RR 1.76, 95% CI 0.43-7.25). Observational studies of semaglutide for weight loss showed no evidence of increased NAION hazards (HR 1.57, 95% CI 0.69-3.59), and RCTs (four NAION events vs one) found no evidence of increased risk (RR 2.18, 95% CI 0.33-14.34). CONCLUSIONS: The absolute rate of NAION in semaglutide users is low. Our novel, stratified analysis provides a more nuanced interpretation than previous pooled reviews, isolating a potential increased risk signal to observational data in the diabetes population only, a finding not corroborated by RCTs. The comprehensiveness of our search and rigorous sensitivity analyses to account for patient overlap in databases strengthen the validity of these conclusions. This synthesis highlights the need for continued pharmacovigilance while contextualising the low absolute risk.
3. Decreased risk of post-thyroidectomy hypocalcemia with history of GLP-1RA use.
In a propensity-matched analysis of 70,665 thyroidectomy patients, prior GLP-1RA/GIP-RA use was associated with a 12% lower risk of hypocalcemia at 0–1 month (RR 0.88). Sensitivity analyses adjusting for postoperative calcitriol use supported this finding, and semaglutide was the only individual agent linked to reduced risk.
Impact: Large, real-world evidence suggests incretin therapy may modulate perioperative calcium homeostasis, informing endocrine surgery care pathways.
Clinical Implications: Consider tailored postoperative calcium/vitamin D supplementation strategies for patients on GLP-1RA/GIP-RA, with close early monitoring; do not extrapolate to long-term outcomes without further evidence.
Key Findings
- Propensity-matched cohorts (n=1,732 per group) showed a 12% lower 0–1 month hypocalcemia risk with preoperative GLP-1RA/GIP-RA exposure (RR 0.88, 95% CI 0.81–0.97).
- Sensitivity analyses accounting for calcitriol use confirmed reduced risk (RR 0.84 with use; RR 0.81 without).
- Semaglutide was the only individual agent associated with reduced short-term hypocalcemia risk.
Methodological Strengths
- Large multi-institutional dataset with propensity score matching and adjustment for relevant covariates.
- Robust sensitivity and subgroup analyses including calcitriol use and agent-specific effects.
Limitations
- Observational design susceptible to residual confounding and misclassification.
- Causality cannot be established; applicability to long-term hypocalcemia beyond 12 months is uncertain.
Future Directions: Prospective studies to confirm causality and mechanistic work on incretin effects on calcium-parathyroid axis in the perioperative setting.
CONTEXT: Recent studies suggest glucagon-like peptide receptor-1 agonists (GLP-1RA) and glucose-dependent insulinotropic polypeptide (GIP) may contribute to altered calcium metabolism. OBJECTIVE: This study examines the association between GLP-1RA/GIP-RA use and risk of post-thyroidectomy hypocalcemia. METHODS: This propensity-matched cohort study utilized the TriNetX Platform to analyze adult patients who underwent total thyroidectomy (2010 to 2024). The intervention cohort included patients with a GLP-1RA or GIP-RA prescription 1 year before thyroidectomy; the control group had no GLP-1RA/GIP-RA history. Propensity score matching controlled for demographics and relevant clinical covariates. Primary outcomes included risk of hypocalcemia at 0-1 month, 1-6 months, and 6-12 months after surgery. Using Poisson regression, odds ratios were reported (alpha = 0.05). RESULTS: Among 70 665 patients, 1759 (2.59%) received a GLP-1RA or GIP-RA. Each matched cohort contained 1732 patients with similar preoperative parathyroid hormone or calcium levels. The GLP-1RA/GIP-RA cohort had a 12% lower risk of hypocalcemia from 0 to 1 month after surgery (relative risk [RR] 0.88; 95% CI: 0.81-0.97). In the sensitivity analysis considering postoperative calcitriol supplementation, recipients with GLP-1RA/GIP-RAs use were less likely to develop hypocalcemia in the month after surgery (RR 0.84; 0.74-0.96), as were those with GLP-1RA/GIP-RAs who never received calcitriol in the month after surgery (RR 0.81; 0.72-0.90). Under subgroup analysis, semaglutide was the sole agent associated with a reduced risk of hypocalcemia. CONCLUSION: Patients with a history of GLP-1RA/GIP-RA use may experience a lower risk of short-term hypocalcemia after thyroidectomy, suggesting personalized supplementation strategies may be required for this population.